Aptevo Therapeutics Inc (APVO):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Aptevo Therapeutics Inc (APVO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9863
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:37
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Aptevo Therapeutics Inc (Aptevo), a subsidiary of Emergent Biosolutions Inc, is a biotechnology company that develops and commercializes oncology and hematology therapeutics. The company’s only marketed product Ixinity that is indicated to replace the missing clotting factor IX in adults and children with hemophilia B. Its pipeline includes immune-oncology candidates for the treatment metastatic castration-resistant prostate cancer, peripheral T-cell lymphoma (PTCL), hematological malignancies, psoriasis and inflammatory bowel disease, and solid tumors. Aptevo is also developing a lead bispecific antibody candidate in collaboration with Alligator Bioscience AB for the treatment of various types of cancer. The company’s immuno-oncology candidates are built on its proprietary Adaptir platform. Aptevo is headquartered in Seattle, Washington, the US.

Aptevo Therapeutics Inc (APVO) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Aptevo Therapeutics and Alligator Bioscience Enter into Co-Development Agreement 10
Equity Offering 12
Aptevo Therapeutics Plans to Raise up to USD17.5 Million in Public Offering of Shares 12
Emergent BioSolutions Completes Spin-Off of Aptevo Therapeutics 13
Asset Transactions 14
Saol Therapeutics Acquires Hyperimmune Products from Aptevo Therapeuticsuni for USD74.5 Million 14
Aptevo Therapeutics Inc – Key Competitors 15
Aptevo Therapeutics Inc – Key Employees 16
Aptevo Therapeutics Inc – Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Recent Developments 18
Financial Announcements 18
Aug 20, 2018: Aptevo Therapeutics deploys Genedata Biologics to streamline Cancer Immunotherapy R&D 18
Aug 09, 2018: Aptevo Therapeutics reports second quarter 2018 financial results 19
May 10, 2018: Aptevo Therapeutics Reports First Quarter 2018 Financial Results 21
Mar 13, 2018: Aptevo Therapeutics Reports 2017 Financial Results and Provides Business Update 23
Nov 09, 2017: Aptevo Therapeutics Reports Third Quarter 2017 Financial Results 25
Aug 10, 2017: Aptevo Therapeutics Reports Second Quarter 2017 Financial Results 27
May 12, 2017: Aptevo Therapeutics Reports First Quarter 2017 Financial Results 28
Mar 31, 2017: Aptevo Therapeutics Reports 2016 Financial Results and Provides Business Update 30
Product News 32
Oct 02, 2017: Aptevo Therapeutics Presents New Data on Enhanced Features of Its Next Generation ADAPTIR Bispecific Platform at the World Bispecific Summit 32
Mar 14, 2017: Aptevo Therapeutics Expands Bispecific Antibody Portfolio 34
Clinical Trials 35
Mar 14, 2017: Aptevo Therapeutics Presents Preclinical Data on New Anti-CD123 ADAPTIR Bispecific Candidate APVO437 at the American Association for Cancer Research 2017 Annual Meeting 35
Other Significant Developments 36
Aug 29, 2017: ImmunoPrecise announces R&D success using the OmniAb® platform to develop fully human antibodies 36
Appendix 37
Methodology 37
About GlobalData 37
Contact Us 37
Disclaimer 37

List of Tables
Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Aptevo Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Aptevo Therapeutics and Alligator Bioscience Enter into Co-Development Agreement 10
Aptevo Therapeutics Plans to Raise up to USD17.5 Million in Public Offering of Shares 12
Emergent BioSolutions Completes Spin-Off of Aptevo Therapeutics 13
Saol Therapeutics Acquires Hyperimmune Products from Aptevo Therapeuticsuni for USD74.5 Million 14
Aptevo Therapeutics Inc, Key Competitors 15
Aptevo Therapeutics Inc, Key Employees 16
Aptevo Therapeutics Inc, Other Locations 17
Aptevo Therapeutics Inc, Subsidiaries 17

List of Figures
Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Aptevo Therapeutics Inc (APVO):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Natural Resource Partners L.P.:企業のM&A・事業提携・投資動向
    Natural Resource Partners L.P. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Natural Resource Partners L.P. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers a …
  • AirAsia Berhad:戦略・SWOT・企業財務分析
    AirAsia Berhad - Strategy, SWOT and Corporate Finance Report Summary AirAsia Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Den-Mat Holdings LLC:医療機器:M&Aディール及び事業提携情報
    Summary Den-Mat Holdings LLC (Den-Mat) is a medical device company that manufactures and develops dental and related products. The company’s products include consumables, small equipment, and a full-service dental laboratory. Its consumables comprise geristore, core paste, tenure, ultra-bond, plashm …
  • Skyworth Digital Holdings Limited:企業の戦略・SWOT・財務分析
    Skyworth Digital Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Skyworth Digital Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Koki Holdings Co Ltd:企業の戦略的SWOT分析
    Koki Holdings Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Denovo Biopharma LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Denovo Biopharma LLC (Denovo Biopharma), formerly Denovo Biomarkers Inc is a biotechnology company that provides novel biomarker solutions to personalize drug development. The company enables drug developers to design new clinical trials in targeted patient population and re-evaluates medici …
  • Greencore Group Plc:戦略・SWOT・企業財務分析
    Greencore Group Plc - Strategy, SWOT and Corporate Finance Report Summary Greencore Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Cerus Corp (CERS):医療機器:M&Aディール及び事業提携情報
    Summary Cerus Corp (Cerus) is a biomedical products company that focuses in the field of blood transfusion safety. It develops and commercializes the INTERCEPT Blood System to enhance blood safety. INTERCEPT Blood System reduces the risk of transfusion-transmitted infections by inactivating a wide r …
  • ARM Ltd.:企業の戦略・SWOT・財務分析
    ARM Ltd. - Strategy, SWOT and Corporate Finance Report Summary ARM Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Tecpetrol SA:企業の戦略的SWOT分析
    Tecpetrol SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Altaba Inc.:企業のM&A・事業提携・投資動向
    Altaba Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Altaba Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, ca …
  • Mustang Survival Corp.:企業の戦略・SWOT・財務情報
    Mustang Survival Corp. - Strategy, SWOT and Corporate Finance Report Summary Mustang Survival Corp. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Ormat Technologies Inc (ORA):電力:M&Aディール及び事業提携情報
    Summary Ormat Technologies, Inc. (Ormat), is a vertically integrated company that focuses on the geothermal and recovered energy generation. The company designs, develops, builds, owns, and operates the geothermal and recovered energy generation (REG) power plants. Ormat also supplies geothermal and …
  • Banco Pan SA (BPAN4):企業の財務・戦略的SWOT分析
    Banco Pan SA (BPAN4) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • CanBas Co Ltd (4575)-製薬・医療分野:企業M&A・提携分析
    Summary CanBas Co Ltd (CanBas) is a clinical stage biopharmaceutical company that provides drugs. The company discovers and develops of novel therapeutics in the field of oncology targeting the cell cycle. It product under development is CBP501, a modified synthetic peptide enhancing the efficacy of …
  • University of Pennsylvania-製薬・医療分野:企業M&A・提携分析
    Summary University of Pennsylvania (UOP) is an educational university that provides distance learning facilities for professional courses. The university offers courses such as art and archaeology, accounting, biochemistry, bioengineering, biomedical graduate studies, city and regional planning, cri …
  • First Solar Inc (FSLR):企業の財務・戦略的SWOT分析
    First Solar Inc (FSLR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Abengoa SA (ABG):電力:M&Aディール及び事業提携情報
    Summary Abengoa SA (Abengoa) is an applied engineering and equipment manufacturer. It employs novel technological solutions for sustainability in infrastructures, energy and water sectors. The company provides integrated project solutions. Abengoa’s solutions include engineering, and operation and m …
  • VINCI Energies:電力:M&Aディール及び事業提携情報
    Summary VINCI Energies S.A. (Vinci), a subsidiary of Vinci SA, is a provider of energy efficiency and renewable energy solutions. The company offers heating, ventilation and air conditioning, electric power, mechanical engineering and information and communications technologies. Vinci operates in mu …
  • CSS Industries, Inc. (CSS):企業の財務・戦略的SWOT分析
    CSS Industries, Inc. (CSS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆